If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Bush has said he believes that global warming is real and has noted that it is a serious problem, but he asserted there is a "debate over whether it's man-made or naturally caused". The Bush Administration's stance on global warming remained controversial in the scientific and environmental communities. Critics have alleged that the administration misinformed the public and did not do enough to reduce carbon emissions and deter global warming.
=== Pharmacodynamics === Etilefrine is an agonist of the α1-adrenergic receptor. It is a vasoconstrictor and antihypotensive agent. It has also been described as a β1-adrenergic receptor agonist with some agonistic actions at the α- and β2-adrenergic receptors. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return, and blood pressure in humans and animals, suggesting stimulation of both α- and β-adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β1 (cardiac) than for β2 adrenoreceptors. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure, and mean arterial pressure of healthy individuals. Peripheral vascular resistance falls during the infusion of 1 to 8 mg etilefrine but begins to rise at higher dosage. Marked falls in pulse rate, cardiac output, stroke volume, and peripheral blood flow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2.5 mg. These findings indicate that etilefrine has both β1- and α1-adrenergic receptor actions in humans.
=== Downworlders === Hypatia Vex — a warlock who owns the Hell Ruelle. Malcolm Fade — High Warlock of London, succeeding Ragnor Fell. Magnus Bane — a powerful warlock, and old friend of Will Herondale's and Tessa Gray's.
Sources: en.wikipedia.org
=== Indian Ocean Forum on Maritime Crime (IOFMC) === The IOFMC enables regional cooperation to form operational responses to maritime crime. This has been implemented as part of the GMCP IO reaction to encourage regional responses. This has enabled the formation of the ‘Prosecutors’ Network’, which allows prosecutors from the different coastal states to coordinate their legal strategies. Legislative reform is consequently possible, and legislation on maritime crime can be created. From this, organisations such as the Southern Route Partnership can be developed.
=== Individualization Phase === Students may complete courses in Individualization Phase, often referred to as the "Indy" Phase, at any of the University of North Carolina School of Medicine campuses or sites. In this phase, the final year of their medical education, students take a variety of elective courses designed to tailor their education toward the specialty they plan to pursue. The phase also includes support for students’ transition into residency.
== Awards and honors == National Outstanding Researcher Award (2019) First Prize in Applied Research Projects, 33rd Khwarizmi International Award (2019) Iran Book of the Year Award (2020), for "Peptide Chemistry in Persian" Distinguished University Professor in Iran, Ministry of Science, Research and Technology (2021) Distinguished Organic Chemistry Professor in Iran, by Iranian Chemical Society (2013) Alexander von Humboldt Foundation Research Fellowship: Awarded multiple research stays (2002, 2004, 2007, 2011, 2014, 2017) Scientific Ambassador of the Alexander von Humboldt Foundation in Iran (2015–2020) Outstanding Researcher Award, K.N. Toosi University of Technology (multiple years)
Sources: en.wikipedia.org
After World War I, the British built the large Singapore Naval Base as part of the defensive Singapore strategy. Originally announced in 1921, the construction of the base proceeded at a slow pace until the Japanese invasion of Manchuria in 1931. Costing $60 million and not fully completed in 1938, it was nonetheless the largest dry dock in the world, the third-largest floating dock, and had enough fuel tanks to support the entire British navy for six months. The base was defended by heavy 15-inch (380 mm) naval guns stationed at Fort Siloso, Fort Canning and Labrador, as well as a Royal Air Force airfield at Tengah Air Base. Winston Churchill touted it as the "Gibraltar of the East", and military discussions often referred to the base as simply "East of Suez". However, the British Home Fleet was stationed in Europe, and the British could not afford to build a second fleet to protect their interests in Asia. The plan was for the Home Fleet to sail quickly to Singapore in the event of an emergency. After World War II broke out in 1939, the fleet was fully occupied with defending Britain, leaving Singapore vulnerable to Japanese invasion.
== Pharmacokinetics == With the once-monthly formulation of paliperidone palmitate, the time to peak is 13 days and the elimination half-life is 25 to 49 days; for the 3-month formulation, the time to peak is 30 to 33 days and the half-life is 84 to 95 days (deltoid muscle) or 118 to 139 days (gluteal). These data come from a 2021 review whose authors included employees of Janssen Research & Development, the manufacturer of paliperidone palmitate. The peak-to-trough ratio of paliperidone palmitate at steady state ranges from 1.56 to 1.70 with the 1- and 3-month formulations. No pharmacokinetic data for the 6-month formulation has been released as of January 2021. However, a 2025 case report described a patient who still had measurable plasma paliperidone concentrations in the low therapeutic range 886 days (2.5 years) after her last injection, indicating that in some individuals the drug may be released from the depot far longer than the predicted half‑life. The pharmacokinetic profile was originally derived from a 2009 pooled analysis of 18,530 paliperidone concentration samples from 1,795 subjects across six Phase I trials and five Phase II and III trials funded by Johnson & Johnson Pharmaceutical Research and Development, LLC. Invega Sustenna, Invega Trinza, and Invega Hafyera all utilize nanoparticle technology. The NanoCrystal® technology used in all three long-acting paliperidone products is manufactured by Alkermes plc.
== External links == International Rett Syndrome Foundation Rett UK Support and Research Charity Reverse Rett UK Rett Registry UK Rett Syndrome Research Trust Ensembl Gene ref Protein ref GeneCard RettBASE: IRSA MECP2 Variation Database Archived 2005-12-17 at the Wayback Machine GeneReview/NIH/UW entry on MECP2-Related Disorders GeneReviews/NCBI/NIH/UW entry on MECP2 Duplication Syndrome UK Site for Families Affected by MECP2. Site for Families Affected by MECP2. Site officiel français sur la duplication MeCP2
Newman stated in September 2015 that a sequel to Garry's Mod was in early development, with Newman looking to include virtual reality content and choose a name other than "Garry's Mod 2". He later announced S&box, a sandbox game using Unreal Engine 4, in September 2017 as a potential spiritual successor to Garry's Mod. By December 2019, development on the game had been paused. Newman resumed development in March 2020 and later moved it to the Source 2 engine. S&box was released on 28 April 2026, to mixed reviews.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.